This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS)

Tipranks - Tipranks - Tue Jun 23, 6:10AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS).

TipRanks' Prime Week Sale - 70% Off

Beta Bionics, Inc. (BBNX)

In a report released today, Matthew O’Brien from Piper Sandler reiterated a Buy rating on Beta Bionics, Inc., with a price target of $20.00. The company’s shares closed last Thursday at $13.88.

According to TipRanks.com, O’Brien has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.9% and a 34.5% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Shoulder Innovations, Inc., and Orchestra BioMed Holdings. ;'>

Currently, the analyst consensus on Beta Bionics, Inc. is a Moderate Buy with an average price target of $17.67, which is a 30.0% upside from current levels. In a report issued on June 8, TipRanks – xAI also upgraded the stock to Buy with a $15.50 price target.

See the top stocks recommended by analysts >>

Regeneron (REGN)

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Regeneron, with a price target of $700.00. The company’s shares closed last Thursday at $609.94.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 10.3% and a 57.3% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Protagonist Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $826.90, which is a 35.1% upside from current levels. In a report issued on June 10, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $669.00 price target.

Alkermes (ALKS)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Alkermes today and set a price target of $43.00. The company’s shares closed last Thursday at $44.99.

According to TipRanks.com, Amsellem is a 5-star analyst with an average return of 12.3% and a 58.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Supernus Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alkermes with a $49.36 average price target, which is a 9.1% upside from current levels. In a report issued on June 15, TipRanks – PerPlexity also upgraded the stock to Buy with a $49.00 price target.

Read More on BBNX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).